skip to main content
Idioma:

Omalizumab decreases exacerbation frequency, oral intake of corticosteroids and peripheral blood eosinophils in atopic patients with uncontrolled asthma

Pelaia, G ; Gallelli, L ; Romeo, P ; Renda, T ; Busceti, M T ; Proietto, A ; Grembiale, R D ; Marsico, S A ; Maselli, R ; Vatrella, A

International journal of clinical pharmacology and therapeutics, 2011-12, Vol.49 (12), p.713-721 [Periódico revisado por pares]

Germany

Texto completo disponível

Citações Citado por
  • Título:
    Omalizumab decreases exacerbation frequency, oral intake of corticosteroids and peripheral blood eosinophils in atopic patients with uncontrolled asthma
  • Autor: Pelaia, G ; Gallelli, L ; Romeo, P ; Renda, T ; Busceti, M T ; Proietto, A ; Grembiale, R D ; Marsico, S A ; Maselli, R ; Vatrella, A
  • Assuntos: Administration, Oral ; Adrenal Cortex Hormones - therapeutic use ; Adult ; Anti-Asthmatic Agents - therapeutic use ; Antibodies, Anti-Idiotypic - therapeutic use ; Antibodies, Monoclonal, Humanized - therapeutic use ; Asthma - blood ; Asthma - drug therapy ; Asthma - physiopathology ; Eosinophils - drug effects ; Female ; Forced Expiratory Volume - drug effects ; Humans ; Hypersensitivity - drug therapy ; Male ; Middle Aged ; Omalizumab
  • É parte de: International journal of clinical pharmacology and therapeutics, 2011-12, Vol.49 (12), p.713-721
  • Notas: ObjectType-Article-1
    SourceType-Scholarly Journals-1
    ObjectType-Feature-2
    content type line 23
  • Descrição: Omalizumab is a humanized monoclonal anti-IgE antibody approved in 2005 by the European Medicine Agency (EMA) for the treatment of severe persistent allergic asthma, which remains inadequately controlled despite optimal therapy with high doses of inhaled corticosteroids and long-acting β₂-adrenergic agonists. Within this context, the present observational study refers to 16 patients currently treated with omalizumab at the Respiratory Unit of "Magna Græcia" University Hospital located in Catanzaro, Italy, whose anti- IgE therapy was started in the period included between March 2007 and February 2010, thus lasting at least 10 months. After 40 weeks of add-on treatment with omalizumab, very relevant decreases were detected, in comparison with pre-treatment mean (± standard deviation) values, in monthly exacerbation numbers (from 1.1 ± 0.6 to 0.2 ± 0.4; p < 0.01) and oral corticosteroid consumption (from 22.6 ± 5.0 to 1.2 ± 2.9 mg/day of prednisone; p < 0.01). These changes were associated with stable improvements in lung function, expressed as increases of both FEV1 (from 53.6 ± 14.6% to 77.0 ± 14.9% of predicted values; p < 0.01) and FEV1/FVC ratio (from 56.3 ± 9.5% to 65.8 ± 9.2%; p < 0.01). Moreover, in 5 patients who persistently had increased numbers of eosinophils (mean ± SD: 15.9 ± 8.0% of total WBC count; absolute number: 1,588.0 ± 956.9/μl) despite a long-lasting therapy with inhaled and systemic corticosteroids, the peripheral counts of these cells decreased down to near normal levels (mean ± SD: 6.3 ± 2.3% of total WBC count; absolute number: 462.0 ± 262.3/μl) after 16 weeks of treatment with omalizumab. Therefore, this descriptive evaluation confirms the efficacy of add-on omalizumab therapy in selected patients with exacerbation-prone, chronic allergic uncontrolled asthma, requiring a continuous intake of oral corticosteroids.
  • Editor: Germany
  • Idioma: Inglês
Links
Voltar para lista de resultados

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.